Business Wire

OCTO-TELEMATICS

20.5.2020 10:03:03 CEST | Business Wire | Press release

Share
OCTO for the “New Normal”

OCTO, a market leader in providing smart solutions by transforming its IoT Big Data set into actionable intelligence for a sustainable connected life, is pleased to announce the launch of two products designed to support companies' return back to business as they transition to the “new normal” following the COVID-19 pandemic. These innovative solutions encourage safe self-distancing and the robust sanitization of vehicles. At the forefront of the design principals, OCTO developed products are easy to implement and manage, while being highly effective. Protecting the workforce and their livelihoods, as well as protecting customers and fostering higher levels of trust.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005174/en/

OCTO AroundMe is based on OCTO’s proven SmartTag technology that utilises the latest Bluetooth standards, OCTO’s IoT cloud platform and is compatible with both iOS and Android smartphones. OCTO AroundMe allows for easy management of social distancing in both public and private spaces, such as stores or office buildings. The pocket-sized SmartTag carried by visitors or employees continuously monitor an individual’s proximity, in this case and under government guidelines this has been automatically set to two metres. Should two people inadvertently have a distance less than two meters apart, an audible alert would remind them to keep a safe distance. The event would also be captured anonymously and stored on the cloud for reporting and analysis, to better understanding and mitigate future risk. To further mitigate any risks, using OCTO AroundMe within closed environments also allows for easy and effective crowd control and building capacity management as it stores all entry and exit information.

OCTO PurePlace uses nano technology originally developed by the National Aeronautics and Space Administration (NASA), that eliminates viruses, bacteria, fungi as well as odours and volatile organic compounds in the air and on surfaces via a purifier. It is a non-invasive solution, safe to people and all materials commonly found within vehicle interiors. As well as the purifier device, the complete OCTO PurePlace solution consists of an onboard telematics device (OCTO SmartDiag or OCTO SuperEasy) and an application compatible with iOS and Android smartphones.

OCTO PurePlace has been designed to protect drivers and passengers across corporate fleets, rental fleets, carsharing and taxi operators. It allows for the easy and effective sanitization of vehicles during a trip with intermittent self-activation and the end of each journey with a full sanitization cycle. To ensure absolute safety and confidence, before entering the vehicle, both the driver and passenger can be notified regarding the state of sanitization via a smartphone app. For the operator and the safe management of the fleet, if the sanitization is not complete, the vehicle may be temporarily suspended from public use.

ABOUT OCTO
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data, generates actionable analytics giving life to a new era of Smart Telematics. Today it has over 6 million connected users and the largest database of vehicle telematics data in the world, with over 267 billion miles of driving data collected and 473,000 claims and insurance events analysed. It also manages over 400,000 vehicle rentals per month.

OCTO does not guarantee, represent or warrant that the use of a photocatalytic oxidation purifier used in the OCTO PurePlace will prevent a vehicle’s occupant(s) from contracting any type of bacteria or virus-based illness, including, but not limited to, the common cold, coronavirus or influenza.

Social Media:

https://www.facebook.com/octotelematicsitalia/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye